Enhanced Molecular Inversion Probes for NGS Target Enrichment
News Feb 04, 2014
Integrated DNA Technologies (IDT) will present its findings on the use of molecular inversion probes (MIPs) for next generation sequencing (NGS) target enrichment at the 15th annual Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, Feb 12-15.
John Havens PhD, Vice-President of Business Development at IDT, will talk about MIPs and their proven effectiveness in the enrichment of genomic content of biological samples for specific regions of interest. NGS can subsequently be used to characterize these regions at high coverage depths.
In comparison to other methods, MIPs provide high multiplexability of targets in a single tube, which combined with the ability to enrich small amounts of DNA, results in time- and cost-effective sequencing.
IDT has developed a procedure whereby a high-fidelity platform is used to synthesize MIPs as long as 200 bases, chemically phosphorylating them independent of sequence. The presence of full length MIPs is then verified using mass spectroscopy prior to pooling.
Barcodes can be directly incorporated via degenerate bases and used to characterize the complexity of target capture. Dr Havens will demonstrate the advantage of these MIPs in terms of target specificity and the capture of longer targets.
A direct comparison will also be given of this approach with hybridization for a set of oncology targets, highlighting the benefits of MIPs over more traditional methods.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE